HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Publié dansJournal of acquired immune deficiency syndromes, vol. 40, no. 3, p. 250-256
Date de publication2005
Résumé
Mots-clés
- Adult
- Aged
- Anti-HIV Agents/administration & dosage/ therapeutic use
- Antiretroviral Therapy, Highly Active
- Biological Markers/blood
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes/immunology
- Chronic Disease
- Female
- HIV Core Protein p24/ blood
- HIV Infections/ drug therapy/immunology
- Hiv-1
- Humans
- Male
- Middle Aged
- Treatment Outcome
Structure d'affiliation
Citation (format ISO)
SCHUPBACH, Jorg et al. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. In: Journal of acquired immune deficiency syndromes, 2005, vol. 40, n° 3, p. 250–256. doi: 10.1097/01.qai.0000181281.75670.56
Fichiers principaux (1)
Article
Identifiants
- PID : unige:7581
- DOI : 10.1097/01.qai.0000181281.75670.56
- PMID : 16249697
ISSN du journal1525-4135